MindBio is a clinical-stage drug development company pioneering psychedelic microdosing research, advancing emerging therapies to treat a range of debilitating health conditions such as depression, anxiety, chronic pain, cognitive impairment and PTSD.
As an innovative leader in research involving LSD and microdosing, MindBio was a perfect fit as a lead sponsor for our recent LSD Conference (our virtual conference exploring the potential of LSD).
The company is currently working on 3 clinical trials with LSD:
- Phase 1 Clinical Trial Microdosing LSD, a world’s first
- Phase 2 Clinical Trial Microdosing LSD in patients with Major Depressive Disorder
- Phase 2 Clinical Trial Microdosing LSD in late stage cancer patients
MindBio co-founder Justin Hanka kicked off the conference with a presentation during the “Emerging Treatments in Mental Health” panel.
After a brief company introduction, Justin Hanka went on to highlight some of the important work being done at MindBio:
“…We’re creating a microdosing regimen using LSD. It’s our first candidate drug, and we’re creating a microdose form that can be effectively prescribed and stored with long shelf life and taken safely in microdoses by patients. We’re running a unique clinical trial, the world’s first of its kind, a Phase one clinical trial in 80 patients who are prescribed the drug by a doctor and take it home as they would with any other medication.
“We have the government approvals and funding to import LSD manipulated in the lab and administer it to the patients. It’s already been running for almost 12 months and it’s due for completion shortly.”
“These clinical trials are also fully-funded”
See here for more information on MindBio’s research and company profile.
And see below for a clip of MindBio’s presentation: